{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-033870","form_type":"8-K","ticker":"SION","cik":"0002036042","company_name":"Sionna Therapeutics, Inc.","filed_at":"2026-05-12T11:08:37+00:00","discovered_at":"2026-05-12T11:10:00.362945+00:00","generated_at":"2026-05-12T11:10:32.033064+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sionna Therapeutics Q1 net loss $26.8M; Phase 2a enrollment completed for SION-719","bullets":["Net loss of $26.8M for Q1 2026, compared to $16.5M in Q1 2025.","R&D expenses $19.0M (vs. $13.7M), G&A expenses $10.6M (vs. $6.0M) year-over-year.","Cash and equivalents $289.9M; expected to fund operations into 2028.","Phase 2a POC trial of SION-719 fully enrolled; topline data expected summer 2026.","Phase 1 dual-combination trial of SION-451 also on track for topline data summer 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-033870","json":"https://secwatch.observer/filing/0001628280-26-033870.json","markdown":"https://secwatch.observer/filing/0001628280-26-033870.md","text":"https://secwatch.observer/filing/0001628280-26-033870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026033870/0001628280-26-033870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026033870/sion-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:10:32.033064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a18cd449a494b58639857cfc22f3141bb26086f7","claim":"Sionna Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $26.8 million.","evidence_excerpt":"Sionna Therapeutics, Inc. issued a press release announcing its financial results and business highlights for the three months ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026033870/0001628280-26-033870-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss was $26.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}